HOME >> MEDICINE >> NEWS
Chemoprevention backgrounder: Working for a future of cancer chemoprevention

Nowadays, a vial of blood taken by a family physician can sometimes forecast a person's risk of heart disease, and cholesterol-lowering drugs as well as a daily baby aspirin may be recommended to curb the threat. But in the future, a simple finger prick also may predict which cancers are destined to develop in an individual, years, even decades, down the road.

And based on a person's unique genetics - the milieu of factors that repair DNA damage, or push cells to grow - the patient of tomorrow also may be given a recipe of drugs that will prevent or delay those cancers from ever developing.

Their cocktail of cancer preventives might include refined forms of aspirin to prevent colon and breast cancer, trace minerals to protect against prostate cancer, or proven versions of ancient remedies, such as turmeric spice for breast cancer and good ole' cups of green tea daily, to repress oral cancer.

At the moment, a complete "chemoprevention" strategy - the use of a natural or synthetic substance to reduce the risk of developing cancer - is a goal to be reached in the future. By all accounts, routine use of such agents won't be here for a long time because much more needs to be understood about the changes that push a cell to become cancerous before that process can be stalled or reversed.

Still, more and more of the research effort at The University of Texas M. D. Anderson Cancer Center is devoted to finding such preemptive strikes - ways to block cancer from ever starting or from becoming clinically apparent.

M. D. Anderson was among the first to look for agents that may help prevent cancer - some three decades ago - and now is seen as a national leader in the field of chemoprevention. In fact, four of five classes of chemopreventive agents the National Cancer Institute has said are promising and so are "considered priority substances for study" are being investigated here, and some of the efforts involve national trials being led
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
16-Nov-2004


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Cancer gene therapy news backgrounder: New ideas fuel next generation gene therapy research
2. Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center
3. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode
4. Working out may keep breast cells working well
5. PAHO Working With Affected Communities In Central America
6. Lupus Foundation Of America Awards Summer Internship To Student Working At Wistar Institute
7. Concerns over the future of childrens health care in British general practice
8. Engineers develop biowarfare sensing elements for future highly sensitive nerve-gas detectors
9. HIV vaccine trial breaks ground for future research
10. Climate change and the future of air travel
11. NIH action plan charts future challenges for liver disease research

Post Your Comments:
(Date:5/22/2013)... Successful Therapy for Parents program, ... in the Silver Lake community of Los Angeles ... progression to existing Parents and Couples counseling programs. ... therapy has always been suggested, but now it's ... specializes in all aspects of relationships ...
(Date:5/22/2013)... Rapids, IA (PRWEB) May 22, 2013 ... theatre piece Handicap This! The performance promotes awareness ... their dreams. The Handicap This! performance will be held ... Mar High School auditorium. Tickets for Handicap This! ... Handicap This! helps audiences measure the level to which ...
(Date:5/22/2013)... City, UT (PRWEB) May 22, 2013 ... the Alabama Health Insurance Exchange . Zane Benefits, ... sponsored health benefits, is the leader in defined ... , According to Zane Benefits’ website, beginning in 2014 ... insurance coverage for individuals and small businesses will become ...
(Date:5/22/2013)... Over the next two decades, the cost of treating ... than double, topping more than $180 billion a year, ... the increase: an aging population. The report, from the ... was published May 22 in the journal Stroke ... system," Dr. Bruce Ovbiagele, chairman of the department of ...
(Date:5/22/2013)... Award Presented at the 2013 Annual M&A ... http://bit.ly/13DkFfk , Merrill Corporation is pleased to ... of the Year” at the 7th M&A Advisor Turnaround ... in Palm Beach, Florida. , Merrill DataSite is ... solution that optimizes the due diligence process and offers ...
Breaking Medicine News(10 mins):Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2Health News:Handicap This! Comes to Marion, Iowa 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3
(Date:5/22/2013)...  The Leukemia & Lymphoma Society (LLS) is committing ... a joint venture between ImmunGene and Caliber, to co-fund ... I clinical trial for a novel fusion protein that ... with indolent lymphomas who do not respond to standard ... is a new class of biotherapeutics produced by fusing ...
(Date:5/22/2013)... 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine. The U.S. Food ... 2010 after a series of trials. These trials found ... pneumococcal types than the previously used PCV7, did not ...
(Date:5/22/2013)... NEW YORK , May 22, 2013 ... Gross LLP is investigating claims on behalf of investors ... (NASDAQ: ISRG ) (CUSIP: 46120E602) who purchased ... April 18, 2013 (the "Class Period"). Such investors are ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ...
Breaking Medicine Technology:The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG 2
Cached News: